{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:37:50Z","timestamp":1793036270561,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.annonc.2023.08.013","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T01:21:32Z","timestamp":1694222492000},"page":"1055-1063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas"],"prefix":"10.1016","volume":"34","author":[{"given":"Y.","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.H.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.annonc.2023.08.013_bib1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2023.08.013_bib2","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.annonc.2023.08.013_bib3","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2023.08.013_bib4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2023.08.013_bib5","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2023.08.013_bib6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.annonc.2023.08.013_bib7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2006.06206.x","article-title":"The role of Janus kinases in haemopoiesis and haematological malignancy","volume":"134","author":"Khwaja","year":"2006","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.annonc.2023.08.013_bib8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41408-018-0138-8","article-title":"Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma","volume":"8","author":"Han","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.annonc.2023.08.013_bib9","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1038\/ncomms7025","article-title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from \u03b3\u03b4-T or NK cells","volume":"6","author":"Kucuk","year":"2015","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.annonc.2023.08.013_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.annonc.2023.08.013_bib11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/sj.onc.1205152","article-title":"Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death","volume":"21","author":"Zamo","year":"2002","journal-title":"Oncogene"},{"issue":"15","key":"10.1016\/j.annonc.2023.08.013_bib12","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quinta\u00b4s-Cardama","year":"2010","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.annonc.2023.08.013_bib13","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A\u00a0phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2023.08.013_bib14","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/blood-2021-148352","article-title":"Phase 2a study of the dual SYK\/JAK inhibitor cerdulatinib (ALXN2075) as monotherapy in patients with relapsed\/refractory peripheral T-cell lymphoma","volume":"138","author":"Horwitz","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.annonc.2023.08.013_bib15","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.3390\/ijms22137109","article-title":"STAT5 as a key protein of erythropoietin signalization","volume":"22","author":"T\u00f3thov\u00e1","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.annonc.2023.08.013_bib16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.annonc.2023.08.013_bib17","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1021\/acs.jmedchem.9b01392","article-title":"Discovery of (2R)-N-[3-[2-[(3-methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a potent and selective Janus kinase 1 (JAK1) inhibitor","volume":"63","author":"Su","year":"2020","journal-title":"J\u00a0Med Chem"},{"issue":"20","key":"10.1016\/j.annonc.2023.08.013_bib18","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.annonc.2023.08.013_bib19","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2023.08.013_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5009\/gnl.2012.6.1.45","article-title":"The immunohistochemical expression of STAT3, Bcl-xL, and MMP-2 proteins in colon adenoma and adenocarcinoma","volume":"6","author":"Lee","year":"2012","journal-title":"Gut and Liver"},{"issue":"1","key":"10.1016\/j.annonc.2023.08.013_bib21","article-title":"Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer","volume":"8","author":"Yang","year":"2012","journal-title":"PLoS One"},{"issue":"282","key":"10.1016\/j.annonc.2023.08.013_bib22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation of incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2023.08.013_bib23","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1182\/blood-2019-125017","article-title":"Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2023.08.013_bib24","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0091270010389469","article-title":"The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers","volume":"51","author":"Shi","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.annonc.2023.08.013_bib25","article-title":"Pharmacokinetic characteristics of golidocitinib, a selective JAK1 inhibitor, in healthy adult participants","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.annonc.2023.08.013_bib26","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2023.08.013_bib27","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood-2018-99-115407","article-title":"Janus kinase (Jak) 1 inhibition affects both megakaryopoiesis and thrombopoiesis","volume":"132","author":"Jarocha","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.annonc.2023.08.013_bib28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/cei.12970","article-title":"Janus kinase inhibitors prevent\u00a0migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production","volume":"189","author":"Mitchell","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.annonc.2023.08.013_bib29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/bjh.14984","article-title":"Mutations in the JAK\/STAT pathway genes and activation of the pathway, a relevant finding in nodal peripheral T-cell lymphoma","volume":"183","author":"Manso","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2023.08.013_bib30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ccell.2023.01.003","article-title":"IDH2 and TET2 mutations synergize to modulate T follicular helper cell functional interaction with the AITL microenvironment","volume":"41","author":"Leca","year":"2023","journal-title":"Cancer Cell"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423008281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423008281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T11:07:55Z","timestamp":1731323275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753423008281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0923753423008281"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2023.08.013","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2023.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}